2021
Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells
Parsons HA, Macrae ER, Guo H, Li T, Barry WT, Tayob N, Wulf GM, Isakoff SJ, Krop IE. Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. JCO Precision Oncology 2021, 5: 896-903. PMID: 34994617, PMCID: PMC9848583, DOI: 10.1200/po.20.00461.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerHER2-positive CTCsHER2-negative metastatic breast cancerObjective response rateBreast cancerHER2-Positive Circulating Tumor CellsHER2-positive metastatic breast cancerResponse rateMedian progression-free survivalPhase II single-arm studyProgressive metastatic breast cancerHER2-negative breast cancerAdvanced breast cancer patientsHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Tumor cellsHER2-positive diseasePrior chemotherapy regimenTumor tissue testingClinical benefit ratePrimary end pointPhase II trialProgression-free survivalGrowth factor receptor 2HER2-negative tumors
2010
Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Jänne PA, Krop IE. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. British Journal Of Cancer 2010, 102: 1495-1502. PMID: 20461092, PMCID: PMC2869174, DOI: 10.1038/sj.bjc.6605676.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsFemaleFluorescent Antibody TechniqueGene AmplificationGenes, erbB-2HumansImmunomagnetic SeparationIn Situ Hybridization, FluorescenceNeoplastic Cells, CirculatingConceptsHuman epidermal growth factor receptor 2Tumor cellsHER2 amplificationBreast cancerCTC yieldEpidermal growth factor receptor 2Growth factor receptor 2Breast cancer patientsSignificant discordance existsFactor receptor 2Lung cancer samplesMedian cell countMetastatic tumor cellsCancer patientsLung cancerMetastatic breastMetastatic tumorsPatient CTCsMetastatic cancerMetastatic tissuesBlood samplesReceptor 2Drug AdministrationCell countPatients